{"id":"NCT03877237","sponsor":"AstraZeneca","briefTitle":"DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction","officialTitle":"International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection Fraction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-09","primaryCompletion":"2020-03-07","completion":"2020-03-07","firstPosted":"2019-03-15","resultsPosted":"2021-05-05","lastUpdate":"2021-05-05"},"enrollment":313,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure With Reduced Ejection Fraction (HFrEF)"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)","primaryOutcome":{"measure":"Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden).","timeFrame":"At baseline and at week 16 or death before week 16","effectByArm":[{"arm":"Dapa 10mg","deltaMin":2.08,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.02164"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":76,"countries":["United States","Brazil","Canada","Denmark","Japan","Slovakia","South Africa","South Korea","Sweden"]},"refs":{"pmids":["39212948","38059368"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169EC00002&amp;attachmentIdentifier=d63ceb7a-2a2d-4a96-9adb-722a4237ce11&amp;fileName=d169ec00002-csp-v2_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169EC00002&amp;attachmentIdentifier=7c255e2c-42d1-4f94-85b7-3724c96b4c0e&amp;fileName=d169ec00002-sap-ed-3_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":156},"commonTop":[]}}